A Clinical Study Evaluating the Safety of Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-DOTA0-Tyr3-Octreotate in Children With Refractory or Recurrent Neuroblastoma Expressing Somatostatin Receptors.

Model scores of the 29,894 trials active now.

Model score 20% for any early termination, 9% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 23% of the time (1,629 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2024-08-30. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: petbraintherapystemmri
  Phrases that lowered it: startfunctionliveruln109
• Sponsor's past termination rate: 23.8% (raises risk) · Sponsor's track record
• Phase: 1 (lowers risk) · Design
• Accepts healthy volunteers: No (raises risk) · Who can join
• Has a data monitoring committee: not given (lowers risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Design: single group (raises risk) · Design
• Drug's FAERS reports with a death: 33.3% (raises risk) · Drug's FDA history
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Trials the sponsor started in the prior 2 years: 7 (raises risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Maximum age: 18 (raises risk) · Who can join
• Collaborators: 1 (raises risk) · Design
• Number of arms: 1 (raises risk) · Design
• Drug's FAERS reports in the prior 12 months: 0 (raises risk) · Drug's FDA history
• Minimum age: 1 (lowers risk) · Who can join

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC) NCT03273712 · started 2017 · scored riskier than 96% of active trials completed
• 67Cu-SARTATE™ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk, Relapsed, Refractory Neuroblastoma NCT04023331 · started 2020 · scored riskier than 79% of active trials terminated
• Phase 1 Study of AlphaMedix™ in Adult Subjects With SSTR (+) NET NCT03466216 · started 2018 · scored riskier than 87% of active trials terminated
• Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201 in NETs NCT02592707 · started 2017 · scored riskier than 85% of active trials terminated
• Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in Subjects With Solid Tumours Expressing Neurotensin Receptor Type 1. NCT03525392 · started 2018 · scored riskier than 81% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.